XOMA News and Press, XOMA Corporation From 03/08/24

2024-03-08 16:44:29 ET More on XOMA XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share Read the full article on Seeking Alpha For further details see: XOMA Corporation files...

2024-03-08 07:36:49 ET More on XOMA XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share XOMA expands portfolio with DSUVIA acquisition; shares tick lower Seeking Alpha’s Q...

Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital Received $15.5 million in cash payments related to our growing royalty base and the achievement of certain development milestones ...

EMERYVILLE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences: The 44 th Annual TD Cowen Health Care Conference taki...

2024-02-24 17:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-16 08:23:48 ET XOMA Corporation ( NASDAQ: XOMA ), a company focused on biopharma royalties, announced an agreement on Friday to acquire clinical-stage biotech Kinnate Biopharma ( NASDAQ: KNTE ) for $2.3352–$2.5879 per share in cash plus a contingent value righ...

EMERYVILLE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today it has entered an agreement to acquire Kinnate Biopharma Inc. (NASDAQ: KNTE) for (i) a base cash price of $2.3352 per share (the Base Price) and (ii) an additional cash amount of not more than $0...

2024-01-23 10:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-18 12:11:26 ET More on XOMA XOMA Preferreds: I Upped My Rating On One Preferred Stock To A Buy Xoma to pay $1M to LadRx as rare disease therapy undergoes FDA review Xoma appoints Owen Hughes as CEO, Jack Wyszomierski as chairman Seeking Alpha’s...

XOMA provided an $8 million non-dilutive royalty capital solution to Talphera XOMA will receive a 15% royalty on all commercial sales and a significant portion of the 75% royalty generated by U.S. Department of Defense purchases XOMA is entitled to no less than 50% of the potent...